IFNγ Stimulator (pharma) is a class of therapeutic agents designed to enhance the production of interferon-gamma (IFNγ), a crucial cytokine in the immune system. These stimulators work by modulating the immune response and activating immune cells, leading to antiviral and anticancer activities. IFNγ stimulators find application in various disease indications, including autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and Crohn's disease, as well as certain cancers and chronic infections. According to WHO, autoimmune diseases affect millions of people in Europe and the USA, with around 2.3 million individuals suffering from multiple sclerosis in Europe alone. Rheumatoid arthritis, another prevalent autoimmune condition, affects more than 2 million adults in the USA. Additionally, the European Cancer Information System reports that over 4.2 million new cancer cases are diagnosed annually in Europe, and around 1.9 million new cancer cases are recorded yearly in the USA. Moreover, chronic infections like tuberculosis remain a concern, with nearly 300,000 reported tuberculosis cases in Europe and around 9,000 cases in the USA.
The growth of the IFNγ stimulator market is driven by the rising incidence of immune-related diseases, advancements in immunotherapy research, promising clinical trial outcomes, and a growing focus on personalized medicine. Companies such as Teva, Viatris, EMD Serono, Worg Pharma, Cullinan Oncology, Fate Therapy, and Mapi Pharma are pharmaceutical companies operating in this category. Moreover, many companies are coming up with new molecules in the space.
Key Developments:
- In Feb 2023, Lee Moffitt Cancer Center in collaboration with Horizon Pharma Ireland completed a phase I/II trial in Breast cancer (Combination therapy) in the USA.
- In March 2023, Inovio Pharmaceuticals presented efficacy data from a phase Ib/IIa trial of MEDI 0457 in Head and neck cancer.
Approved IFNγ Stimulator molecules
- Multikine (leukocyte interleukin injection)
- Actimmune (interferon gamma-1 b)
IFNγ Stimulator Pipeline Molecules
- ALT-801
- MEDI0457
- TG1042
- GEN-001
- NIZ985
- BNT151
- INO-5151
- RTX-321
Clinical Activity and Development of IFNγ Stimulator
In the IFNγ Stimulator space, there are very few companies, conducting more than more than 100 clinical trials in this category of drugs. For instance,
- In May 2021, Horizon Therapeutics presented pooled efficacy data from four trials of Interferon gamma-1b in Idiopathic pulmonary fibrosis at the 117th International Conference of the American Thoracic Society (ATS-2021)
- In April 2020, Interim safety and efficacy data from a phase II trial in Breast cancer was presented at the 111th Annual Meeting of the American Association for Cancer Research
|
Product Name |
Total Studies |
|
ALT-801 |
6 |
|
MEDI0457 |
6 |
|
TG1042 |
5 |
|
GEN-001 |
3 |
Target Indication Analysis of Interferon Gamma Stimulator Market
IFNγ stimulators are therapeutic agents designed to enhance the production of interferon-gamma (IFNγ), a key cytokine in the immune response. Target indications for IFNγ stimulators include various immune-mediated disorders such as chronic infections, certain cancers, and autoimmune diseases. By boosting IFNγ levels, these stimulators aim to modulate immune responses, activate immune cells, and promote antiviral and anticancer activities. Moreover, IFNγ stimulators hold potential in treating conditions like multiple sclerosis, Crohn's disease, and rheumatoid arthritis by regulating immune function and inflammation. Their development and application offer promising prospects for addressing complex immunological conditions and advancing precision medicine approaches.
Frequently Asked Questions
IFN gamma Stimulator drugs are used in the management of chronic infections, certain cancers, and autoimmune diseases.
The growth of the IFN gamma stimulator market is driven by the rising incidence of immune-related diseases, advancements in immunotherapy research, promising clinical trial outcomes, and a growing focus on personalized medicine
The major players in this space are ImmunityBio, Inovio, AstraZeneca, BioNTech, CEL-SCI, Clinigen, Genome & Company, Horizon Therapeutics, LG Chem, and Novartis.
The IFN gamma stimulator market faces significant restraints due to limited awareness and understanding of IFN?-based therapies among healthcare professionals and patients, leading to slower adoption rates. Additionally, the high cost of IFN? stimulators and potential side effects associated with their use create challenges in their widespread implementation.
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- ImmunityBio
- Inovio
- AstraZeneca
- BioNTech
- CEL-SCI
- Clinigen
- Genome & Company
- Horizon Therapeutics
- LG Chem
- Novartis
- Orient Europharma
- Rubius Therap
- Stamford Pharma
- Teva
- Transgene